Castle Creek Acquires Fibrocell, Now Leading Development of FCX-007 Gene Therapy for RDEB
Castle Creek Pharmaceutical recently acquired Fibrocell Science and is now leading the development of treatments for epidermolysis bullosa (EB), including the investigational gene therapy FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The companies had previously established a partnership to develop FCX-007. “Our organizations have a shared…